ArticleJournal of cellular physiology2010
Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells.
Article in Journal of cellular physiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 citations in OpenAlex.
- Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD.Molecular therapy. Methods & clinical development · 2023Article
- Beovu, but not Lucentis impairs the function of the barrier formed by retinal endothelial cells in vitro.Scientific reports · 2022Article
- Visual acuity and progression of macular atrophy in patients receiving intravitreal anti-VEGF for age-related macular degeneration.European journal of ophthalmology · 2022Article
- Retinal and Choroidal Vascular Diseases: Past, Present, and Future: The 2021 Proctor Lecture.Investigative ophthalmology & visual science · 2021Article
- COCO/DAND5 inhibits developmental and pathological ocular angiogenesis.EMBO molecular medicine · 2021Article
- Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates.Translational vision science & technology · 2021Article
- Low risk to retina from sustained suppression of VEGF.The Journal of clinical investigation · 2019Review
- Long-term therapeutic effect in nonhuman primate eye from a single injection of anti-VEGF controlled release hydrogel.Bioengineering & translational medicine · 2019Article
- Combined SIRT3 and SIRT5 deletion is associated with inner retinal dysfunction in a mouse model of type 1 diabetes.Scientific reports · 2019Article
- Article
- AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases.Acta ophthalmologica · 2018Review
- Reversible retinal vessel closure from VEGF-induced leukocyte plugging.JCI insight · 2017Article
- A safety study of high concentration and high frequency intravitreal injection of conbercept in rabbits.Scientific reports · 2017Article
- Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage.Science translational medicine · 2017Article
- Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab.International journal of ophthalmology · 2017Article
- Hypoxia-Inducible Factor-1α Target Genes Contribute to Retinal Neuroprotection.Frontiers in cellular neuroscience · 2017Review
- The Effect of Ranibizumab on Normal Neurosensory Retina in the Eyes of Patients with Exudative Age Related Macular Degeneration.The open ophthalmology journal · 2017Article
- Ten years of anti-vascular endothelial growth factor therapy.Nature reviews. Drug discovery · 2016Article
- Experimental scleral cross-linking increases glaucoma damage in a mouse model.Experimental eye research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
It has recently been reported that relatively short-term inhibition of vascular endothelial growth factor (VEGF) signaling can cause photoreceptor cell death, a potentially clinically important finding since VEGF blockade has become an important modality of treatment of ocular neovascularization and macular edema. However, in a set of studies in which we achieved extended and complete blockage of VEGF-induced vascular leakage through retinal expression of a VEGF binding protein, we did not observe any toxicity to retinal neurons. To follow-up on these apparently discrepant findings, we designed a set of experiments with the kinase inhibitor SU4312, which blocks phosphorylation of VEGF receptors, to look directly for evidence of VEGF inhibition-related retinal toxicity. Using transgenic mice with sustained expression of VEGF in photoreceptors, we determined that periocular injection of 3 microg of SU4312 every 5 days markedly suppressed subretinal neovascularization, indicating effective blockade of VEGF signaling. Wild-type mice given periocular injections of 5 microg of SU4312 every 5 days for up to 12 weeks showed normal scotopic and photopic electroretinograms (ERGs), no TUNEL stained cells in the retina, and no reduction in outer nuclear layer thickness. Incubation of cultured ganglion cells or retinal cultures containing photoreceptors with high doses of SU4312 did not reduce cell viability. These data suggest that blocking VEGF signaling in the retina for up to 12 weeks does not damage photoreceptors nor alter ERG function and should reassure patients who are receiving frequent injections of VEGF antagonists for choroidal and retinal vascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.